A Phase 4 interventional study of Afrezza Dose 1 and Afrezza Dose 2 in Diabetes Mellitus, Type 1 and Diabetes Mellitus, Type 2, sponsored by Mannkind Corporation. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-18.
Sponsored by Mannkind Corporation · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Diabetes Mellitus, Type 1 by Mannkind Corporation — 1 open to participants now, 1 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Mannkind Corporation.
Among the 21 studies in Diabetes Mellitus, Type 1 by Mannkind Corporation, this one is the 15th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2021, is one of 3 in phase 4, and was the 17th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →1 of the 21 studies in Diabetes Mellitus, Type 1 by Mannkind Corporation is open now, in 1 country. Recruiting first, the newest first:
Mannkind Corporation · Sites in United States
Ages 6–17
By country, each count listing its studies:
Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 34 across the 18 interventional studies, 326 across the 2 observational. Of the 19 that completed or were terminated, 10 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mannkind Corporation is the lead sponsor of 57 studies on the registry; 3 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.
1 of the studies in Diabetes Mellitus, Type 1 by Mannkind Corporation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07224321Mannkind CorporationINHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Diabetes Mellitus, Type 1 by Mannkind Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
MKC-TI-191 is a Phase 4, single-arm, multicenter, proof-of-concept clinical trial evaluating the efficacy and safety of Afrezza, administered according to the current Afrezza prescribing information (PI) compared to a titrated dose, in combination with a basal insulin in adult subjects (≥18 years of age) with type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM). Eligible subjects will be on a stable regimen consisting of a basal bolus insulin therapy prior to screening. The study is composed of up to 4 clinic visits (screening, 2 treatment visits, and a follow-up visit). Two individual doses of Afrezza will be administered during a meal challenge at Visits 2 and 3. The duration of each subject's participation in the trial is expected to be approximately 2 weeks.
Screening (Visit 1): Informed consent and California Experimental Subjects Bill of Rights will be signed and eligibility confirmed. Eligible subjects will be enrolled at Visit 1.
Subjects will come into the clinic in a fasting state for a meal challenge and individual dose of Afrezza during Visits 2 and 3. At the beginning of each visit, before their dose of Afrezza, subjects will have FEV1 measurements taken in the clinic. Each meal challenge will consist of 1 to 2 bottles of nutritional shake to be fully consumed within 15 minutes. The nutritional shake will contain approximately 240 calories, 41 g carbohydrate, 10 g protein, and 4 g fat per bottle. Each Afrezza dose will be administered at the start of the meal challenge.
Visit 2: The first dose of Afrezza will be based on the dose of subcutaneous (SC) rapid-acting analogue (RAA) insulin that the subject would normally take, converted according to the guidelines provided in the current Afrezza prescribing information. If subject's normal RAA dose is \<4 units or 5 units, subject will be asked to consume enough nutritional shake, per their normal I:C ratio, to cover an RAA dose of 4 units or ≥6 units such that their Afrezza dose at Visit 3 is higher than the dose taken at Visit 2. After completing the standardized meal challenge, the Investigator will decide, based on the subject's glucose excursion at Visit 2, if the subject should proceed to Visit 3 where a second dose of Afrezza will be administered.
Visit 3: The second dose of Afrezza will be based on the dose of SC RAA that the subject would normally take, converted by multiplying their RAA dose by 2 and rounding down to the nearest Afrezza cartridge size.
Follow-up Visit (Visit 4): Subjects will return for safety assessments, including a final FEV1 measurement, 24 to 72 hours after their last dose of Afrezza.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects will be asked to provide a recent negative COVID-19 test (if available), confirm they have no symptoms of COVID-19, or provide evidence of COVID-19 vaccination.
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The test product is defined as Afrezza \[insulin human\] inhalation powder administered using the Afrezza inhaler. In addition, subjects will take their personal basal insulin while enrolled in the study.
Combination Product: Afrezza Dose 1 · Combination Product: Afrezza Dose 2
The first dose of Afrezza will be based on the dose of subcutaneous rapid-acting analogue (RAA) insulin that the subject would normally take for the standardized meal, converted according to the guidelines provided in the current Afrezza U.S. prescribing information.
The second dose of Afrezza will be based on the dose of subcutaneous rapid-acting analogue that the subject would normally take for the standardized meal, converted by multiplying their RAA dose by 2 and rounding down to the nearest Afrezza cartridge size.
Post-prandial Glucose Excursion
Mean glucose change from baseline (or postprandial glucose excursion \[PPGE\]) based on self-monitored blood glucose (SMBG) at 15, 30, 45, 60, 90 and 120 minutes after the dose of Afrezza with baseline defined as SMBG at the time of the dose of Afrezza (t=0)
Time frame: 120 minutes post-dose
Number of Subjects With at Least 1 Event of Level 1 Hypoglycemia
Number of subjects with at least 1 event (also referred to as incidence) of Level 1 hypoglycemia (\<70mg/dL) within the 120 minutes after Afrezza dosing as confirmed by SMBG.
Time frame: 120 minutes
Percent of Level 1 Hypoglycemia
Percent of total SMBG measurements \<70 mg/dL (Level 1 hypoglycemia) within the 120 minutes after Afrezza dosing.
Time frame: 120 minutes
Number of Subjects With at Least 1 Event of Level 2 Hypoglycemia
Number of subjects with at least 1 event (also referred to as incidence) of Level 2 hypoglycemia (\<54mg/dL) within the 120 minutes after Afrezza dosing as confirmed by SMBG.
Time frame: 120 minutes
Percent of Level 2 Hypoglycemia
Percent of total SMBG measurements \<54 mg/dL (Level 2 hypoglycemia) within the 120 minutes after Afrezza dosing
Time frame: 120 minutes
Number of Subjects With At Least 1 Event of Severe Hypoglycemia
Number of subjects with at least 1 event (also referred to as incidence) of severe hypoglycemia, defined as events requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions within the 120 minutes after Afrezza dosing.
Time frame: 120 minutes
Change in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Between Two Points, Baseline and 120 Minutes Post-Afrezza Dose
Change in percent predicted forced expiratory volume in 1 second (FEV1) between two points (value at 120 minutes post-Afrezza dose minus value at baseline). Standard deviation was not reported.
Time frame: 120 minutes post-dose
Between April 2021 and May 2021, a total of 20 subjects were enrolled at two investigational sites in the US.
| Milestone | Afrezza |
|---|---|
| Started | 20 |
| Completed | 20 |
| Not completed | 0 |
| Milestone | Afrezza |
|---|---|
| Started | 20 |
| Completed | 20 |
| Not completed | 0 |
Mean glucose change from baseline (or postprandial glucose excursion \[PPGE\]) based on self-monitored blood glucose (SMBG) at 15, 30, 45, 60, 90 and 120 minutes after the dose of Afrezza with baseline defined as SMBG at the time of the dose of Afrezza (t=0)
| mg/dL | Afrezza Dose 1 | Afrezza Dose 2 |
|---|---|---|
| 15 minutes PPGE | 6.8 ± 3.3 | 5.6 ± 2.5 |
| 30 minutes PPGE | 25.9 ± 5.7 | 21.9 ± 5.6 |
| 45 minutes PPGE | 48.9 ± 6.9 | 27.0 ± 6.6 |
| 60 minutes PPGE | 64.2 ± 7.9 | 34.3 ± 8.1 |
| 90 minutes PPGE | 82.8 ± 14.3 | 36.0 ± 10.2 |
| 120 minutes PPGE | 88.6 ± 17.7 | 36.9 ± 13.1 |
Number of subjects with at least 1 event (also referred to as incidence) of Level 1 hypoglycemia (\<70mg/dL) within the 120 minutes after Afrezza dosing as confirmed by SMBG.
| Participants | Afrezza Dose 1 | Afrezza Dose 2 |
|---|---|---|
| Number of Subjects With at Least 1 Event of Level 1 Hypoglycemia | 0 | 1 |
Percent of total SMBG measurements \<70 mg/dL (Level 1 hypoglycemia) within the 120 minutes after Afrezza dosing.
| SMBG Measurements | Afrezza Dose 1 | Afrezza Dose 2 |
|---|---|---|
| Percent of Level 1 Hypoglycemia | 0 | 2 |
Number of subjects with at least 1 event (also referred to as incidence) of Level 2 hypoglycemia (\<54mg/dL) within the 120 minutes after Afrezza dosing as confirmed by SMBG.
| Participants | Afrezza Dose 1 | Afrezza Dose 2 |
|---|---|---|
| Number of Subjects With at Least 1 Event of Level 2 Hypoglycemia | 0 | 1 |
Percent of total SMBG measurements \<54 mg/dL (Level 2 hypoglycemia) within the 120 minutes after Afrezza dosing
| SMBG Measurements | Afrezza Dose 1 | Afrezza Dose 2 |
|---|---|---|
| Percent of Level 2 Hypoglycemia | 0 | 1 |
Number of subjects with at least 1 event (also referred to as incidence) of severe hypoglycemia, defined as events requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions within the 120 minutes after Afrezza dosing.
| Participants | Afrezza Dose 1 | Afrezza Dose 2 |
|---|---|---|
| Number of Subjects With At Least 1 Event of Severe Hypoglycemia | 0 | 0 |
Change in percent predicted forced expiratory volume in 1 second (FEV1) between two points (value at 120 minutes post-Afrezza dose minus value at baseline). Standard deviation was not reported.
| change in percent predicted FEV1 | Afrezza Dose 1 | Afrezza Dose 2 |
|---|---|---|
| Change in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Between Two Points, Baseline and 120 Minutes Post-Afrezza Dose | 0.63 ± 8.25 | -2.55 ± 5.78 |
Collected over Duration of the two treatment visits (~8 hours). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Afrezza Dose 1 | 0/20 (0%) | 0/20 (0%) | 1/20 (5%) |
| Afrezza Dose 2 | 0/20 (0%) | 0/20 (0%) | 2/20 (10%) |
| Event | Afrezza Dose 1 | Afrezza Dose 2 |
|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 1/20 | 2/20 |
| Age, Continuous(years) | Afrezza |
|---|---|
| Mean | 51.2 ± 13.90 |
| Sex: Female, Male(Participants) | Afrezza |
|---|---|
| Female | 10 |
| Male | 10 |
| Ethnicity (NIH/OMB)(Participants) | Afrezza |
|---|---|
| Hispanic or Latino | 4 |
| Not Hispanic or Latino | 16 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Afrezza |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 15 |
| More than one race | 0 |
| Unknown or Not Reported | 4 |
| Region of Enrollment(participants) | Afrezza |
|---|---|
| United States | 20 |
| HbA1c(percentage of Hemoglobin A1c) | Afrezza |
|---|---|
| Mean | 6.66 ± 0.84 |
| Diabetes type(Participants) | Afrezza |
|---|---|
| Type 1 diabetes | 18 |
| Type 2 diabetes | 2 |
| BMI(kg/m^2) | Afrezza |
|---|---|
| Mean | 26.9 ± 6.97 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2021 to primary completion in May 2021, 1 month.
Results were first posted in Sep 2023, 2 years 3 months after primary completion.
Of 74 phase 4 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's 1 month is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.